Company intelligence / Profile preview

Neumora Therapeutics, Inc.

Watertown, Massachusetts, United Statesir.neumoratx.com ↗

Ownership: Public · NMRA
Development stage: Phase 2

Overview

The company's lead program navacaprant did not meet its primary endpoint in the KOASTAL-1 Phase 3 study for MDD announced in January 2025. The company has paused KOASTAL-2 and -3 studies and plans to resume them in March 2025 with optimized site selection and enhanced medical monitoring. Data from KOASTAL-3 is expected in Q1 2026 and KOASTAL-2 in Q2 2026. The company has discontinued a Phase 2 trial of navacaprant for bipolar depression to prioritize resources for the KOASTAL program.

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule drugs
Industry: Biotech

Drug pipeline

12 assets

navacaprant

11 more assets in the full pipeline.

Request access →

Financials

Market cap: $211.2M
Total revenue: $0
Enterprise value: $94.7M

Beyond the preview

Go deeper on Neumora Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Neumora Therapeutics, Inc..

Explore the full profile